Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alzheimer's Disease Diagnostics

This article was originally published in Start Up

Executive Summary

New tests for Alzheimer's Disease could be a boon for biopharma and for patients.

You may also be interested in...

New Alzheimer's Disease Target and a Potentially Broad Drug Discovery Approach

Researchers have identified a new target in Alzheimer's disease--the natural substrate of an enzyme that itself has long been a target for AD drug development. That the molecule appears to be druggable is itself a surprising observation that may offer valuable insight into how to improve AD drugs. More than that, however, it suggests that substrates of protease inhibitors may provide a completely new set of drug targets in a variety of diseases.

A More Detailed Image of Alzheimer's Disease

Even as researchers continue the debate around whether the plaque formation characteristic of Alzheimer's Disease precedes or follows the neurological abnormalities that eventually cause dementia, a new imaging study has shown that plaques are a critical mediator in AD development, bolstering the notion that removing them or ultimately targeting the processes that lead to plaque formation are valid therapeutic strategies.

Alzheimer's R&D: Tweaking Venture's Risk-Reward Ratio

Building Alzheimer's-focused companies remains difficult, in part because venture capital remains scarce. But advancese in diagnostic and imaging tools, improved means of measuring the impact of drugs on cognition, and a better understanding of therapeutic targets mean investment risks are improving, say some executives and VCs. Can Alzheimer's attract more mainstream VC investment and pay off with more lucrative deals like Pfizer's acquisition of Rinat?

Related Content


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts